Previously writing on printed circuit technology products manufacturer Trackwise Designs (TWD), in March with the shares down to 0.65p I noted “Contract and Trading Update” disastrous, cash crunch AHOY!. What now of a “UK EV OEM Contract Update”?

Previously writing on printed circuit technology products manufacturer Trackwise Designs (TWD), in January I noted its 1p per share equity raise and concluded that its still-remaining financial challenge meant it remains that hopefully my prior warnings were heeded; avoid/sell. Today a “Contract and Trading Update” announcement…and the shares are currently more than 40% lower at 0.65p, so what’s the situation now?

Previously writing on transplant platform company Verici Dx (VRCI), in September with the shares falling to 17.5p I reviewed was the fundraise for accelerated progress or to avert cash crunch ahoy?, concluding continue to avoid. The shares most recently closed at 7.5p, but what of them currently up 20% today on the back of a “CLIA Certificate of Compliance” announcement.

Previously writing on transplant platform company Verici Dx (VRCI), in June with the shares down to 26p I questioned was the “fundraise to… continue the accelerated progress” or to avert cash crunch ahoy?. Now half-year results... and the shares currently further down to 17.5p.

An announcement from ‘regenerative medicine medical devices company’ Tissue Regenix (TRX) – and the shares currently above 1p, more than 55% higher. Though “New collaboration with leading healthcare company” ramptastic?...

‘Regenerative medicine’ medical devices company Tissue Regenix (TRX) has updated including that currently “the San Antonio facility remains fully operational” and the company “has not experienced any material reduction in net revenues versus expectations”. However, the shares have currently responded to below 0.40p, circa 35% lower…

Shares in ‘regenerative medical devices’ group Tissue Regenix (TRX) are currently approaching 20% higher on the day, at around 1.20p, on the back of an update including “it is anticipated that delayed orders will be dispatched over the coming weeks… All processing in the company's United States facility has also resumed with immediate effect”…

An announcement from Tissue Regenix (TRX), a Woodford pick (uh oh), at an intra-day 10:02am (uh oh); “Notice of cyber security incident”. Oh dear! – and particularly considering the company’s previous announcement included that it only “believes that the available cash runway will continue to support the working capital requirement of the company until the end of April 2020”!...

A “Trading Update” from Woodford stock Tissue Regenix (TRX) – and the shares currently around 1.40p, down (natch!) approaching 20%...

Oh dear oh dear oh dear. I commented at the weekend HERE that AIM- and now Nasdaq-listed Mereo Biopharma (AIM: MPH, Nasdaq: MREO) has FY18 results due this Monday, following Mereo’s merger with Oncomed on Nasdaq. Duly reported, how’s that extended cash runway doing?

Previously writing on Nanoco Group (NANO) in October with the shares at 55p, I concluded that still a very high asking price for the ‘jam tomorrow’ story with cash burn concerns; sell. The following updates with the shares currently further lower below 30p on the back of a “Full Year Trading Update and Outlook” announcement…

A “Trading Statement” announcement from Microsaic Systems (MSYS) includes Chairman Eric Yeatman commenting “we are very encouraged with the progress since our 21 March 2017 update, when we introduced our biopharma strategy, specifically around bioprocessing. We are engaging with several of the leading players in the global market for bioprocessing equipment”. However, the statement also includes that “the company now expects its H1 and full year 2017 revenue to be significantly lower than for 2016”. Hmmm…